(Q46594720)

English

The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.

scientific article published in March 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

acute decompensated heart failure

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

14

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Beth A. Davison

17

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

18

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Christopher M O'Connor

24

object named as

Christopher M O'Connor

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

Piotr Ponikowski

15

object named as

Piotr Ponikowski

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

John R Teerlink

1

object named as

John R Teerlink

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Adriaan A Voors

16

object named as

Adriaan A Voors

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Michael M Givertz

13

object named as

Michael M Givertz

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Barry M. Massie

25

object named as

Barry M Massie

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Howard C Dittrich

23

object named as

Howard Dittrich

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

8

object named as

Ileana L Piña

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

11

object named as

Michael R Zile

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

George A. Mansoor

22

object named as

George A Mansoor

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul J Hauptman

5

object named as

Paul J Hauptman

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Christina M Salerno

21

object named as

Christina M Salerno

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

3

object named as

Jay P Mohr

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

author name string

Vicente J Iragui

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Peter E Carson

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

David H Lovett

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Alan B Miller

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Scott Thomson

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul D Varosy

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Denise Wolko

19

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Paul Delucca

20

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

35

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

233-244

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment e

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The pilot Stroke Data Bank: definition, design, and data

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The adenosine kinase hypothesis of epileptogenesis

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

What can adenosine neuromodulation do for neuroprotection?

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Antithrombotic therapy for cerebrovascular disorders. An update

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS).

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

The role of intracellular 3'5'-cyclic adenosine monophosphate (cAMP) in atherosclerosis

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine receptors and the central nervous system.

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Adenosine receptors and neurological disease: neuroprotection and neurodegeneration

1 reference

https://api.crossref.org/works/10.2165%2F11594680-000000000-00000

21 January 2018

Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/22339573

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11594680-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/22339573

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46594720&oldid=2207966990"